Intellia reports case of liver toxicity in ATTR gene editing study
Intellia Therapeutics disclosed that one patient in a Phase 3 study of its gene editing treatment for a progressive heart disease experienced a serious case of elevated liver enzymes. The patient with...
View ArticleTaysha’s pivotal trial plans; Keros to stop work on PAH drug, lay off 45% of...
Plus, news about Immunic, Neurocrine Biosciences, Alcon, AusperBio and Evommune: Taysha Gene Therapies reveals plans for pivotal trial, $200M offering: The biotech on Wednesday disclosed design details...
View ArticleBig pharma companies explain why tariffs will harm US investments
The first wave of biopharma comments on industry-specific tariffs is here. As of Thursday morning, just over 300 of at least 950 public comments have been released by the Department of Commerce in...
View ArticleEisai, Merck stave off generic competition to Lenvima
Eisai and Merck succeeded in stopping Shilpa Medicare Ltd. from launching a generic version of Lenvima for at least another decade, Eisai said Thursday. The Japanese pharma company said it received a...
View ArticleThe preventive care rebrand
As more healthcare startups pile on the longevity trend, I’ve noticed something familiar about the services they’re touting. Take Midi Health’s new AgeWell program. The virtual care company, best known...
View ArticleUS urges Supreme Court to decline Oklahoma PBM case
The US Supreme Court will continue deciding whether to take up a pivotal case on state PBM regulation after the federal government offered its stance on the issue. The US solicitor general this week...
View ArticleAstellas licenses Claudin18.2 ADC from China’s Evopoint Biosciences
Astellas is the latest large pharmaceutical company to ink a deal with a Chinese biotech, paying $130 million upfront for a Claudin18.2-targeted antibody-drug conjugate from Evopoint Biosciences. The...
View ArticleSummit says bispecific misses overall survival in closely-watched lung cancer...
Summit Therapeutics and Akeso’s PD-1xVEGF bispecific hit on progression-free survival in a keenly-awaited Phase 3 lung cancer trial, but missed the other primary endpoint of overall survival. The news...
View ArticleAnother Bristol Myers exec goes to Acadia; David Southwell takes CEO job at...
→ Allyson McMillan-Youngblood has left Bristol Myers Squibb to join Acadia Pharmaceuticals as SVP of its rare disease franchise. She had a 22-year career at Bristol Myers, becoming SVP and business ...
View Article#ASCO25: Pfizer's Braftovi combo doubles survival time for some colorectal...
Adding Pfizer’s BRAF inhibitor Braftovi to a cocktail of cancer drugs cut the risk of death by half for certain colorectal cancer patients, according to results from a Phase 3 trial. The combination of...
View ArticleFormer Sen. Kyrsten Sinema on ibogaine and psychedelics
It may not come as a surprise that one of the most unconventional US senators in recent memory has taken a keen interest in a peculiar yet powerful psychedelic that could be used to treat ...
View ArticleAs a challenging first half nears a close, biopharma uncertainty persists
What will the second half of 2025 bring for biopharma? It's a tough question to answer after a slog of stock-moving proposals out of Washington dampened the cheery sentiment at the start of the year ...
View ArticleRoche’s 96-week data for multiple sclerosis drug; ZymeWorks claims $20M...
Plus, news about Diakonos Oncology and Coherus: Roche’s longer-term data for multiple sclerosis drug: The Swiss drugmaker’s BTK inhibitor fenebrutinib achieved an annualized relapse rate of 0.06 in 93...
View ArticleSummit’s disappointing survival readout raises stakes for full data
Summit Therapeutics’ mixed results for its potential competitor to Merck’s Keytruda left an important question unanswered: How mature, exactly, were the data? The biotech on Friday shared new Phase 3...
View ArticleNew CDC vaccine schedule at odds with HHS announcement
The CDC officially axed Covid-19 shot recommendations for pregnant women from its vaccine schedule, following a social media announcement earlier this week from HHS chief Robert F. Kennedy Jr. and...
View ArticleAstraZeneca agrees to pay $51M to settle ‘pay-for-delay’ class action suit
AstraZeneca and Handa Pharmaceuticals have agreed to pay a combined $51.4 million to resolve a class action lawsuit that claimed they unlawfully delayed the availability of cheaper generic versions of...
View ArticleHHS loses bid to go ahead with firings, reorganization
Health and Human Services Secretary Robert F. Kennedy Jr. will have to refrain from carrying out his plan to revamp the federal health agencies through broad firings after an appeals court on Friday...
View ArticlePatient dies in Rocket gene therapy trial; Lilly’s $1B deal for a non-opioid...
Welcome back to Endpoints Weekly! The last week in May brought a lot of news, and it isn’t over yet. We’ve got reporters on the ground at the ASCO meeting in Chicago this weekend, so ...
View Article#ASCO25: Arvinas, Pfizer's PROTAC in breast cancer no better than oral SERDs
After Pfizer spent $1 billion upfront to license a targeted protein degrader from Arvinas, the latest clinical results suggest that the drug overall is no better than similar pills called SERDs....
View Article#ASCO25: Gilead, Merck reveal 'practice-changing' data for Trodelvy-Keytruda...
CHICAGO — Gilead and Merck made a strong case for combining Trodelvy and Keytruda in the first-line setting for an aggressive form of breast cancer. The combination of Trodelvy and Keytruda reduced the...
View Article#ASCO25: Enhertu extends life by three months for some stomach cancer patients
CHICAGO — For AstraZeneca and Daiichi Sankyo, the antibody drug conjugate Enhertu has become a recurring topic at the annual American Society of Clinical Oncology meeting. Their latest data presented...
View Article#ASCO25: Immatics reports more early-stage data for melanoma cell therapy...
Immatics has shared new survival data from a Phase 1b trial of its melanoma cell therapy candidate, bolstering expectations for a registrational study that it recently started. At an average follow-up...
View ArticleFDA approves Moderna’s next-gen Covid vaccine
The FDA has approved Moderna’s next-generation Covid-19 vaccine, but said that people aged 12 to 64 should only get the shot if they have a health condition that puts them at risk from the virus ...
View Article